LONDON, November 14, 2014 /PRNewswire/ --
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
Gilead Sciences Inc.'s stock lost 2.53%, to close the day at $104.20. The stock recorded a trading volume of 20.86 million shares, above its three months average volume of 14.97 million shares. The company's shares oscillated between $103.51 and $107.05 during the session. Over the last one month and over the past three months, Gilead Sciences Inc.'s shares have advanced 2.72% and 10.87%, respectively. Further, the stock has surged 38.75% since the start of this year. The company's stock is trading above its 200-day moving average of $88.92, while the 200-day moving average is below Gilead Sciences Inc. stock's 50-day moving average of $106.15. Additionally, the stock traded at a PE ratio of 18.43 and has a Relative Strength Index (RSI) of 49.49. Sign up and read the free notes on GILD at:
On Thursday, shares in MannKind Corp. recorded a trading volume of 5.28 million shares, lower than its three months average volume of 6.71 million shares. The stock ended the day at $6.18, which was 1.64% above its previous day's closing of $6.08, and registered an intraday range of $6.08 and $6.36. MannKind Corp.'s shares have surged 5.10% in the previous three trading sessions, 34.06% in the last one month, and 18.85% on YTD basis. The company's stock is trading above its 50-day moving average of $5.92, which is below the stock's 200-day moving average of $7.10. Furthermore, shares of MannKind Corp. have an RSI of 56.78. The complimentary notes on MNKD can be downloaded as in PDF format at:
ARIAD Pharmaceuticals Inc.'s stock declined 3.40% to end Thursday's session at $6.25. The stock recorded a trading volume of 4.59 million shares, below its three months average volume of 6.36 million shares. The company's shares fluctuated between $6.16 and $6.62 during the session. ARIAD Pharmaceuticals Inc.'s shares have fallen by 8.36% since the beginning of 2014. However, the stock has gained 24.50% over the last one month and 9.65% in the previous three months. The company's stock is trading above its 50-day moving average. ARIAD Pharmaceuticals Inc. stock's 200-day moving average of $6.62 is above its 50-day moving average of $5.73. Additionally, the stock has an RSI of 65.86. Register for free on Investor-Edge and access the latest research on ARIA at:
On Thursday, shares in iBio Inc. fluctuated between $1.07 and $1.15 before ending the session 2.70% lower at $1.08. The stock reported a trading volume of 0.91 million shares, lower than its three months average volume of 5.69 million shares. Although iBio Inc.'s stock has lost 12.20% in the previous three trading sessions and 55.92% in the last one month, it has rallied 140.90% in the past three months and 222.39% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $1.04 and $0.61, respectively. Moreover, shares of iBio Inc. have an RSI of 47.82. The complete research on IBIO is available for free at:
Celgene Corp.'s stock finished Thursday's session 0.76% lower at $107.43. A total of 3.27 million shares were traded, which was below its three months average volume of 4.88 million shares. The stock vacillated between $106.54 and $109.17 during the session. Over the last one month and over the past three months, Celgene Corp.'s shares have advanced 22.81% and 21.51%, respectively. Additionally, from the beginning of 2014, the stock has gained an upside of 27.16%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $96.48 is greater than its 200-day moving average of $84.36. Celgene Corp.'s stock traded at a PE ratio of 36.81 and has an RSI of 69.60. Free in depth research on CELG is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.